NEVANAC 1 mg/ml eye drops, suspension
nepafenac
NEVANAC contains the active substance nepafenac which belongs to a group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs).
NEVANAC is used in adults:
To prevent and relieve eye pain and inflammation after cataract surgery in the eye.
To reduce the risk of macular edema (swelling in the back of the eye) after cataract surgery in the eye in diabetic patients.
Consult your doctor, pharmacist, or nurse before starting to use NEVANAC.
Avoid exposure to sunlight during treatment with NEVANAC.
It is not recommended to wear contact lenses after cataract surgery. Your doctor will tell you when you can start wearing contact lenses again (see also “NEVANAC contains benzalkonium chloride”).
Do not use this medicine in children and adolescents under 18 years old as the safety and efficacy in this population have not been established.
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines.
NEVANAC may affect or be affected by other medicines you are using, including other eye drops for the treatment of glaucoma.
Tell your doctor if you are using medicines that reduce blood clotting (warfarin) or other NSAIDs. These medicines may increase the risk of bleeding.
If you are pregnant or might become pregnant, consult your doctor before using NEVANAC. Women who may become pregnant are advised to use effective contraceptive methods during treatment with NEVANAC. The use of NEVANAC is not recommended during pregnancy. Do not use NEVANAC unless clearly indicated by your doctor.
If you are breastfeeding, NEVANAC may pass into breast milk. However, no effects on the breastfed child are expected. NEVANAC can be used during breastfeeding.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, consult your doctor or pharmacist before using this medicine.
Do not drive or use machines until your vision is clear. Immediately after applying NEVANAC, you may notice that your vision becomes blurred.
This medicine contains 0.25 mg of benzalkonium chloride in each 5 ml equivalent to 0.05 mg/ml.
NEVANAC contains a preservative, benzalkonium chloride, which may be absorbed by soft contact lenses and may alter the color of contact lenses. Remove contact lenses before using this medicine and wait 15 minutes before putting them back. Benzalkonium chloride may cause eye irritation, especially if you have dry eyes or other corneal diseases (the transparent layer on the front of the eye). Consult your doctor if you feel any unusual sensation, itching, or pain in the eye after using this medicine.
Follow exactly the instructions of administration of this medicine indicated by your doctor or pharmacist. In case of doubt, consult your doctor or pharmacist again.
Use NEVANAC only in your eyes. Do not swallow or inject.
One drop in the affected eye(s), three times a day, morning, noon, and night. Use it at the same time every day.
Start 1 day before cataract surgery. Continue on the day of surgery. Then use it for the period of time that your doctor indicates, which may be up to 3 weeks (to prevent and relieve eye pain and inflammation) or 60 days (to prevent macular edema) after your surgery.
Wash your hands before starting.
If you are applying drops to both eyes, repeat the above steps for the other eye. Replace the cap on the bottle immediately after use.
If a drop falls outside the eye, try again.
If you are using other eye drops, wait at least 5 minutes between applying NEVANAC and the other drops.
Contact your doctor for detailed instructions. Do not apply more drops until it is time for your next dose.
Apply a single dose as soon as you remember. If it is almost time for your next dose, do not apply the missed dose. Continue with your regular dosing schedule. Do not use a double dose to make up for missed doses. Do not apply more than one drop 3 times a day in the affected eye(s).
Do not stop using NEVANAC without consulting your doctor. You can usually continue using the eye drops unless the side effects are severe. If these effects worry you, talk to your doctor or pharmacist.
If you have any other questions about using this medicine, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
You may have a higher risk of experiencing corneal side effects (problems on the surface of the eye), if you:
Contact your doctor immediately if your eyes become red or if the pain increases while using the drops. This may be due to inflammation of the surface of the eye with or without loss or damage to cells or inflammation of the colored part of the eye (iritis). These side effects have been observed in up to 1 in 100 people.
The following side effects have also been observed with NEVANAC 1 mg/ml eye drops, suspension or NEVANAC 3 mg/ml eye drops, suspension or with both:
Uncommon(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 1,000 people)
Frequency not known(frequency cannot be estimated from the available data)
If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if it is possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the bottle and carton after EXP. The expiry date is the last day of the month shown.
Do not store above 30°C.
To avoid infections, discard the bottle 4 weeks after first opening. Write the date of opening on the space provided on the bottle label and carton.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Small amounts of sodium hydroxide and/or hydrochloric acid are added to maintain normal acidity levels (pH levels).
NEVANAC is a liquid (a pale yellow to orange suspension) supplied in a carton containing a 5 ml plastic bottle with a screw cap.
Novartis Europharm Limited
Vista Building
Elm Park,
Merrion Road
Dublin 4
Ireland
Novartis Manufacturing NV
Rijksweg 14
2870 Puurs-Sint-Amands
Belgium
Novartis Pharma GmbH
Roonstrasse 25
90429 Nuremberg
Germany
Novartis Pharma GmbH
Sophie-Germain-Strasse 10
90443 Nürnberg
Germany
You can request more information about this medicine from the local representative of the marketing authorisation holder.
België/Belgique/Belgien Novartis Pharma N.V. Tél/Tel: +32 2 246 16 11 | Lietuva SIA Novartis Baltics Lietuvos filialas Tel: +370 5 269 16 50 |
Luxembourg/Luxemburg Novartis Pharma N.V. Tél/Tel: +32 2 246 16 11 | |
Ceska republika Novartis s.r.o. Tel: +420 225 775 111 | Magyarország Novartis Hungária Kft. Tel.: +36 1 457 65 00 |
Danmark Novartis Healthcare A/S Tlf: +45 39 16 84 00 | Malta Novartis Pharma Services Inc. Tel: +356 2122 2872 |
Deutschland Novartis Pharma GmbH Tel: +49 911 273 0 | Nederland Novartis Pharma B.V. Tel: +31 88 04 52 111 |
Eesti SIA Novartis Baltics Eesti filiaal Tel: +372 66 30 810 | Norge Novartis Norge AS Tlf: +47 23 05 20 00 |
Österreich Novartis Pharma GmbH Tel: +43 1 86 6570 | |
España Novartis Farmacéutica, S.A. Tel: +34 93 306 42 00 | Polska Novartis Poland Sp. z o.o. Tel.: +48 22 375 4888 |
France Novartis Pharma S.A.S. Tél: +33 1 55 47 66 00 | Portugal Novartis Farma - Produtos Farmacêuticos, S.A. Tel: +351 21 000 8600 |
Hrvatska Novartis Hrvatska d.o.o. Tel. +385 1 6274 220 | România Novartis Pharma Services Romania SRL Tel: +40 21 31299 01 |
Ireland Novartis Ireland Limited Tel: +353 1 260 12 55 | Slovenija Novartis Pharma Services Inc. Tel: +386 1 300 75 50 |
Ísland Vistor hf. Sími: +354 535 7000 | Slovenská republika Novartis Slovakia s.r.o. Tel: + 421 2 5542 5439 |
Italia Novartis Farma S.p.A. Tel: +39 02 96 54 1 | Suomi/Finland Novartis Finland Oy Puh/Tel: +358 (0)10 6133 200 |
Sverige Novartis Sverige AB Tel: +46 8 732 32 00 | |
Latvija SIA “Novartis Baltics” Tel: +371 67 887 070 |
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu